Soros Fund Management - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 22 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
Soros Fund Management ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2021$20,801,000
+6.1%
32,298,0000.0%0.39%
+5.4%
Q4 2020$19,611,000
+44.8%
32,298,000
+65.2%
0.37%
+11.4%
Q3 2020$13,548,00019,552,0000.33%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2020
NameSharesValueWeighting ↓
HIGHBRIDGE CAPITAL MANAGEMENT LLC 55,943,000$34,742,0001.33%
PenderFund Capital Management Ltd. 5,000,000$3,839,0000.98%
Context Capital Management, LLC 7,485,000$4,494,0000.62%
Opti Capital Management, LP 7,000,000$4,250,0000.47%
Soros Fund Management 32,298,000$19,611,0000.37%
Shaolin Capital Management LLC 7,000,000$4,175,0000.29%
Weiss Asset Management LP 3,500,000$2,084,0000.09%
CSS LLC/IL 2,825,000$1,681,0000.06%
GABELLI & Co INVESTMENT ADVISERS, INC. 225,000$137,0000.02%
LAZARD ASSET MANAGEMENT LLC 25,000,000$15,009,0000.02%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders